Skip to main content
. Author manuscript; available in PMC: 2015 Apr 15.
Published in final edited form as: Pediatr Allergy Immunol. 2013 Jun 16;24(5):476–486. doi: 10.1111/pai.12095

Table 2. Association between severe eczema and comorbid atopic disease.

Comorbid atopic disease Mild or moderate eczema Severe eczema P-value#
Freq Percent (95% CI) Freq Percent (95% CI)
Asthma
Ever asthma 2226 24.3 (22.3, 26.4) 201 36.9 (28.5, 45.2) 0.002
Asthma within the past 12 months 1705 19.0 (17.0, 20.9) 169 32.2 (24.1, 40.2) 0.0003
Asthma severity < 0.0001
 Mild 1110 64.1 (58.3, 69.9) 73 36.7 (23.9, 49.5)
 Moderate 485 30.4 (24.7, 36.1) 61 27.2 (16.2, 38.2)
 Severe 108 5.5 (3.4, 7.6) 35 36.1 (20.5, 51.7)
Hay fever
Hay fever within the past 12 months 3252 34.1 (31.7, 36.5) 253 39.0 (30.7, 47.3) 0.26
Hay fever severity < 0.0001
 Mild 2124 61.4 (56.7, 66.0) 86 31.1 (21.6, 40.7)
 Moderate 960 33.9 (29.2, 38.6) 109 39.7 (28.9, 51.5)
 Severe 162 4.6 (3.3, 5.9) 57 29.1 (18.5, 39.7)
Food allergies
Food allergies within the past 12 months 1436 14.1 (12.5, 15.7) 157 27.0 (19.2, 34.7) < 0.0001
Food allergy severity < 0.0001
 Mild 660 47.9 (41.6, 54.2) 35 18.1 (9.1, 27.1)
 Moderate 421 28.0 (22.7, 33.3) 60 32.5 (18.9, 46.0)
 Severe 344 23.3 (18.2, 28.3) 61 48.6 (31.8, 65.4)
#

Rao-Scott chi-square test

Parental refusal to answer a particular question or response of “don't know” occurred for the questions pertaining to eczema severity in 22 (0.2%), ever asthma in 104 (0.1%), current asthma in 107 (0.2%), asthma severity in 13 (0.3%), current hay fever in 154 (0.2%), hay fever severity in 49 (0.3%), current food allergy in 120 (0.2%) and food allergy severity in 30 (0.6%), respectively.

Note: The proportional odds assumption was not met (Score test, P<0.01). Therefore, ordinal logistic regression was not used. Rather, all analyses of severity used binary logistic regression on dichotomized severe vs. mild-moderate disease. However, similar results were obtained when severity was dichotomized moderate-severe vs. mild.

HHS Vulnerability Disclosure